AG
KDNY

Aperio Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Aperio Group’s Portfolio KDNY Stock Details KDNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-189
Closed -$1K – 2857
2019
Q2 		$1K Buy
+189
New +$2.88K ﹤0.01% 2994
2018
Q2 		– Sell
-2,029
Closed -$94K – 2291
2018
Q1 		$94K Buy
+2,029
New +$74.3K ﹤0.01% 2219

Other funds holding KDNY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Aperio Group's KDNY Position: Q3 2019 in Review

Aperio Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2019, closing a stake of 189 shares — an estimated $1K sold.

Aperio Group first reported a position in KDNY in Q1 2018 and held it in 2 quarters. The position peaked at $94K in Q1 2018. 88 funds tracked by Wall St. Rank hold KDNY as of Q3 2019.

  • Aperio Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 189 Chinook Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1K.
  • Aperio Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Aperio Group's Chinook Therapeutics, Inc. Common Stock position peaked at $94K in Q1 2018.
  • 88 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.